ORIC vs. OCS, ZYME, ICPT, NRIX, MLYS, JANX, RPTX, TBPH, TRDA, and ME
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Oculis (OCS), Zymeworks (ZYME), Intercept Pharmaceuticals (ICPT), Nurix Therapeutics (NRIX), Mineralys Therapeutics (MLYS), Janux Therapeutics (JANX), Repare Therapeutics (RPTX), Theravance Biopharma (TBPH), Entrada Therapeutics (TRDA), and 23andMe (ME). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals vs.
Oculis (NASDAQ:OCS) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
ORIC Pharmaceuticals received 28 more outperform votes than Oculis when rated by MarketBeat users. However, 75.00% of users gave Oculis an outperform vote while only 60.66% of users gave ORIC Pharmaceuticals an outperform vote.
14.3% of Oculis shares are owned by institutional investors. Comparatively, 91.3% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.3% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ORIC Pharmaceuticals' return on equity of 0.00% beat Oculis' return on equity.
In the previous week, ORIC Pharmaceuticals had 3 more articles in the media than Oculis. MarketBeat recorded 6 mentions for ORIC Pharmaceuticals and 3 mentions for Oculis. ORIC Pharmaceuticals' average media sentiment score of 0.45 beat Oculis' score of 0.31 indicating that Oculis is being referred to more favorably in the media.
Oculis currently has a consensus target price of $33.40, suggesting a potential upside of 171.54%. ORIC Pharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 92.06%. Given ORIC Pharmaceuticals' higher probable upside, equities analysts plainly believe Oculis is more favorable than ORIC Pharmaceuticals.
Oculis has higher revenue and earnings than ORIC Pharmaceuticals.
Summary
Oculis beats ORIC Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ORIC Pharmaceuticals Competitors List
Related Companies and Tools